The Technology
LipimetiX' technology was
developed through the intimate
knowledge of structure and function of the amphipathic helix in Apolipoproteins.
Amphipathic helical structure of Apo E
Non-polar
surface
Polar
surface
Lipoprotein
Surface

LipimetiX

Reconstituting the Reverse
Cholesterol Transport Pathway

small peptides that mimic the structure and function of the receptor binding (polar) and lipid binding (non-polar) domains of Apolipoprotein E. The peptides insert into lipid rich lipoproteins and directs them to receptors on the liver. The lipoproteins are then internalized and degraded, dramatically decreasing blood cholesterol levels.
LipimetiX' lead peptide, AEM-18, is only 18 amino acids, and inserts into LDL as well as VLDL remnants, clearing these cholesterol rich lipoproteins from the blood, even in the absence of the LDL receptor.
lipimetix,4_llc001002.gif lipimetix,4_llc001002.gif lipimetix,4_llc002001.jpg lipimetix,4_llc001002.gif
AEM-28, is a 28 amino acid peptide that
combines the amphipathic lipid binding
domain of Apo E to the human receptor
binding domain of Apo E
Scientists at the University of Alabama, Birmingham, designed and synthesized